Life Sciences, Год журнала: 2025, Номер 377, С. 123800 - 123800
Опубликована: Июнь 4, 2025
Язык: Английский
Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(3)
Опубликована: Фев. 1, 2025
Abstract With the incorporation of immune checkpoint inhibitors into treatment endometrial cancer (EC), a deeper understanding tumor microenvironment is critical. Tertiary lymphoid structures (TLSs) are considered favorable prognostic factors for EC, but significance their spatial distribution remains unclear. B cell receptor repertoire analysis performed using six TLS samples located at various distances from showed that TLSs in distal areas had more shared clones with tumor-infiltrating lymphocytes. To comprehensively investigate TLSs, we developed an artificial intelligence model to detect and determine locations whole-slide images. Our effectively quantified were detected 69% patients EC. We identified them as proximal or margin demonstrated (dTLSs) significantly prolonged overall survival progression-free (PFS) across multiple cohorts [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.36–0.88; p = 0.01 survival; HR, 0.58; CI, 0.40–0.84; 0.004 PFS]. When analyzed by molecular subtype, dTLSs copy-number-high EC subtype longer PFS (HR, 0.51; 0.29–0.91; 0.02). Moreover, higher response rate (87.5 vs. 41.7%) trend toward improved PFS. findings indicate functions implications may vary locations, serve predictors efficacy. This facilitate personalized therapy
Язык: Английский
Процитировано
1
Oncogene, Год журнала: 2025, Номер unknown
Опубликована: Март 8, 2025
Abstract The interleukin-36 (IL-36) family comprises of three pro-inflammatory receptor agonists (IL-36α, IL-36β and IL-36γ), two anti-inflammatory antagonists (IL-36RA IL-38) along with the IL-36 (IL-36R). Part IL-1 cytokine superfamily, was discovered in early 2000s due to homology its member sequences cytokines. As pro- cytokines, respectively, IL-36α, IL-36β, IL-36γ IL-38 aid maintaining homoeostasis by reciprocally regulating body’s response damage disease through IL-36R-associated signalling. With significant roles immune realised, interest has grown investigating their cancer. While initial studies indicated solely tumour-suppressing roles, more recent work identified tumour-promoting cancer, suggesting a complex dual functionality activity cancer is similarly complex, antagonist displaying distinct tumour-suppressive particularly colorectal (CRC), addition broad various other malignancies. This review provides comprehensive overview activation IL-36R signalling, physiological functions these
Язык: Английский
Процитировано
1
MedComm, Год журнала: 2024, Номер 5(3)
Опубликована: Март 1, 2024
Abstract Cancer is a major cause of death globally, and traditional treatments often have limited efficacy adverse effects. Immunotherapy has shown promise in various malignancies but less effective tumors with low immunogenicity or immunosuppressive microenvironment, especially sarcomas. Tertiary lymphoid structures (TLSs) been associated favorable response to immunotherapy improved survival cancer patients. However, the immunological mechanisms clinical significance TLS malignant are not fully understood. In this review, we elucidate composition, neogenesis, immune characteristics tumors, as well inflammatory development. An in‐depth discussion unique TLSs lung cancer, breast melanoma, soft tissue sarcomas will be presented. Additionally, therapeutic implications TLS, including its role marker prognosis, strategies promote formation maturation explored. Overall, aim provide comprehensive understanding tumor microenvironment suggest potential interventions for treatment.
Язык: Английский
Процитировано
6
Molecular Cancer, Год журнала: 2024, Номер 23(1)
Опубликована: Ноя. 14, 2024
Liver metastases are commonly detected in the advanced stages of various malignant tumors, representing a significant clinical challenge. Throughout process liver formation, immune cells play pivotal role, particularly pre-metastatic and metastatic niches within liver. Immune establish extensive intricate interactions with tumor other components liver, collectively promoting sustaining growth metastases. Despite limited efficacy existing therapeutic modalities against some metastases, novel immune-based treatment approaches continuously being explored validated. Building on systematic elucidation immunosuppressive characteristics we potential immunotherapies applicable to patients from multiple dimensions.
Язык: Английский
Процитировано
6
International Journal of Surgery, Год журнала: 2023, Номер unknown
Опубликована: Май 29, 2023
Tertiary lymphoid structures (TLS) are the lymphocyte aggregates that play a key role in vast majority of solid tumors including colon cancer, displaying an antitumor effect under most circumstances. The heterogeneity between left- and right-sided cancer (LCC RCC) encompasses various aspects, such as clinical manifestations, pathological features, immune responses. However, function prognostic significance TLS within LCC RCC have yet to be fully understood.A retrospective analysis was performed on 2612 patients who underwent radical resection for or without distant metastasis multiple medical centers. Utilizing propensity score matching, 121 with were selected training set. An external validation set 64 also employed. Hematoxylin-eosin immunohistochemical staining used assess proportion cells. Clinical characteristics values analyzed. Nomograms constructed predict 3-year 5-year overall survival (OS), respectively.For patients, located interstitial region outside tumor tissue mainly consisted B cells T quantity density higher than those LCC. In multivariate Cox regression analysis, ( P =0.014), vascular invasion =0.019), AJCC stage =0.026) independent factors OS RCC. For =0.024), differentiation =0.001), budding =0.040) emerged OS. Similar results obtained verification Separate nomograms developed, improved prediction performance compared 8th edition TNM staging system.Differences observed RCC, suggesting nomogram based could more effectively patients. Furthermore, recommended better patient survival. Taken together, these suggested at left right side substantially different, which may lead use different model development individual treatment strategy.
Язык: Английский
Процитировано
12
Scandinavian Journal of Immunology, Год журнала: 2023, Номер 97(6)
Опубликована: Март 25, 2023
Mesenchymal stromal/stem cells (MSCs) possess the ability to self-renew and differentiate into other cell types. Because of their anti-inflammatory immunomodulatory abilities, as well more ready availability compared stem sources, MSCs hold great promise for treatment many diseases, such haematological defects, acute respiratory distress syndrome, autoimmunity, cardiovascular etc. However, immune rejection remains an important problem. are considered have low immunogenicity, but they do not full immunological privilege. This review analyzes discusses safety from perspective with aim providing a reference future research clinical application.
Язык: Английский
Процитировано
11
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Дек. 4, 2023
The success of immunotherapy approaches, such as immune checkpoint blockade and cellular with genetically modified lymphocytes, has firmly embedded the system in roadmap for combating cancer. Unfortunately, majority cancer patients do not yet benefit from these therapeutic even when prognostic relevance response their tumor entity been demonstrated. Therefore, there is a justified need to explore new strategies inducing anti-tumor immunity. recent connection between formation ectopic lymphoid aggregates at sites patient prognosis, along an effective response, suggests that manipulating occurrence tertiary structures (TLS) may play critical role activating against growing tumor. However, mechanisms governing TLS clear understanding substantial heterogeneity are still lacking. Here, we briefly summarize current state knowledge regarding driving development, outline impact on clinical outcomes patients, discuss appropriate systems modeling help identify protective patients.
Язык: Английский
Процитировано
11
Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)
Опубликована: Март 18, 2024
Immunotherapy, particularly immune checkpoint inhibitor (ICIs) therapy, stands as an innovative therapeutic approach currently garnering substantial attention in cancer treatment. It has become a focal point of numerous studies, showcasing significant potential treating malignancies, including lung and melanoma. The objective this research is to analyze publications regarding immunotherapy for colorectal (CRC), investigating their attributes identifying the current areas interest cutting-edge advancements. We took into account from 2002 2022 included Web Science Core Collection. Bibliometric analysis visualization were conducted using CiteSpace, VOSviewer, R-bibliometrix, Microsoft Excel. quantity associated with domain been steadily rising over years, encompassing 3753 articles 1498 reviews originating 573 countries regions, involving 19,166 institutions, 1011 journals, 32,301 authors. In field, China, United States, Italy are main that come forward publishing. journal greatest impact factor CA-A Cancer Journal Clinicians. Romain Cohen leads number publications, while Le Dt out most influential author. microenvironment infiltration emerging key hotspots future directions domain. This carries extensive bibliometric examination cancer, aiding researchers understanding points, possible avenues research, recognizing forthcoming development trends.
Язык: Английский
Процитировано
4
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Июль 4, 2024
Immunotherapy shows substantial advancement in cancer and is becoming widely used clinical practice. A variety of biomarkers have been proposed to predict the efficacy immunotherapy, but most them low predictive ability. Tertiary lymphoid structures (TLSs), aggregation multiple lymphocytes, found exist various tumor tissues. TLSs shown correlate with patient prognosis immunotherapy response. This review summarizes characteristics inducing factors TLS formation, presents available evidence on role predicting response different cancers, lastly emphasizes their potential for neoadjuvant efficacy.
Язык: Английский
Процитировано
4
Cancer Medicine, Год журнала: 2024, Номер 13(14)
Опубликована: Июль 1, 2024
Abstract Background Colorectal cancer (CRC) is among the most hackneyed malignancies. Even patients with identical clinical symptoms and same TNM stage still exhibit radically different outcomes after receiving equivalent treatment regimens, indicating extensive heterogeneity of CRC. Myriad molecular subtypes CRC have been exploited for decades, including compelling consensus subtype (CMS) classification that has broadly applied patient stratification biomarker‐drug combination formulation. Encountering barriers to translation, however, CMS fails fully reflect inter‐ or intra‐tumor As a consequence, addressing precisely managing unique characteristics remain arduous tasks clinicians. Review In this review, we systematically summarize further elaborate on their applications, limitations, future orientations. Conclusion recent years, exploration through cell lines, animal models, patient‐derived xenografts (PDXs), organoids, trials contributes refining biological insights unraveling subtype‐specific therapies in Therapeutic interventions nanotechnology, clustered regulatory interspaced short palindromic repeat/CRISPR‐associated nuclease 9 (CRISPR/Cas9), gut microbiome, liquid biopsy are powerful tools possibility shift immunologic landscape outlook precise medicine.
Язык: Английский
Процитировано
4